Vanderbilt University School of Medicine

Nashville, Tennessee 37235

4 studies enrolling now · 36 studies all time

What they study most

Acute Kidney Injury, Acute Respiratory Failure, Bipolar I Depression, Carcinoma, Hepatocellular, Colonic Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer, Colorectal Neoplasms, Covid19, Delirium, Dengue, Diabetic Kidney Disease (DKD)

Studies at this site

• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) — Recruiting now
• Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates — Recruiting now
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas — Recruiting now
• A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). — Recruiting now
• A Trial of Setmelanotide in Acquired Hypothalamic Obesity — Running, not enrolling
• EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway — Completed
• Open-Label Extension Study of Setmelanotide — Completed
• A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer — Running, not enrolling
• Open-Label Study of Setmelanotide in Hypothalamic Obesity — Completed
• Transthyretin Amyloidosis Outcome Survey (THAOS) — Completed
• Darbe Administration in Newborns Undergoing Cooling for Encephalopathy — Completed
• A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) — Stopped early
• Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease — Completed
• Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity — Completed
• Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19 — Stopped early
• Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome — Completed
• Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity — Completed
• An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS — Status unconfirmed
• An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS — Status unconfirmed
• A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS — Withdrawn before enrolling
• Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis — Completed
• "Dusting" Versus "Basketing" - Treatment Of Intrarenal Stones — Completed
• Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer — Completed
• Impact of Neuromonitoring During Cardiac Procedures — Completed
• Third International Study on Mechanical Ventilation — Completed
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer — Completed
• Trial of Antimycobacterial Therapy in Sarcoidosis — Completed
• A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care — Stopped early
• Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support) — Completed
• Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults — Completed
• Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis — Completed
• A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression — Completed
• The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study — Stopped early
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults — Completed
• Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults — Completed